[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-381107-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-381107-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tislelizumab-for-squamous-lung-cancer-combined-with-basal-cell-carcinoma-of-the-skin-a-case-report","Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin - A case report","","Surgery is the preferred treatment for basal cell carcinoma (BCC), but locally advanced or metastatic cases may require radiotherapy or systemic therapy. Programmed death receptor 1 (PD-1) inhibitors are rarely used for cutaneous BCC. This report describes a 74-year-old man with BCC of the back and squamous lung cancer, treated with docetaxel plus nedaplatin combined with tislelizumab PD-1 immunotherapy, resulting in marked size reduction of both tumors, resolution of the back mass, healing of the wound, and shrinkage of the lung tumor after two cycles.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tislelizumab-for-squamous-lung-cancer-combined-with-basal-cell-carcinoma-of-the-skin-a-case-report/381107/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tislelizumab-for-squamous-lung-cancer-combined-with-basal-cell-carcinoma-of-the-skin-a-case-report/381107.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What cancers were diagnosed in this case?","Question",{"text":63,"@type":64},"The patient was diagnosed with basal cell carcinoma (BCC) and squamous lung cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment combination was used?",{"text":68,"@type":64},"Docetaxel plus nedaplatin systemic chemotherapy was combined with tislelizumab immunotherapy (PD-1 inhibitor).",{"name":70,"@type":61,"acceptedAnswer":71},"What were the treatment outcomes after tislelizumab?",{"text":72,"@type":64},"After two cycles, the lung tumor shrank, the back mass disappeared, and the wound healed, with both cancers significantly reduced in size.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},381107,1790798519,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":124},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","®  \n Clinical Case Report   \nTislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin  \nA case report  \nMing-Jun Wu, MMa ,b  , Yu-Chun Chen, MMa ,b , Xiao-Li Cui, MMa ,b , Qian Yang, MMa , Qing-Liang Xue, MD, PhDa,*  \n\n| Abstract\u003Cbr>Introduction: Surgery is the preferred treatment for basal cell carcinoma (BCC), locally advanced or metastatic BCC, radiation therapy or systemic therapy can be considered. Programmed death receptor 1 (PD-1) inhibitors are rarely used to treat cutaneous BCC. In the present case, we found that tislelizumab, a PD-1 immunosuppressant, had a positive effect on BCC.\u003Cbr>Patient concerns: A 74-year-old male patient presented with a mass in the left back in October 2021, which was surgically removed and diagnosed as BCC. The patient was diagnosed with squamous lung cancer after presenting with a cough and coughing up a small amount of white, sticky sputum in December 2021.\u003Cbr>Diagnosis: BCC and squamous lung cancer.\u003Cbr>Interventions: Docetaxel + nedaplatin systemic chemotherapy combined with tislelizumab immunotherapy.\u003Cbr>Outcomes: Both BCC and squamous lung cancer were significantly reduced in size.\u003Cbr>Conclusion: After 2 cycles of immunotherapy with tislelizumab, the lung tumor shrank, the back mass disappeared, and the wound healed.\u003Cbr>Abbreviations: BCC = basal cell carcinoma, CT = computed tomography, HHI = hedgehog pathway inhibitors, IgG = immunoglobulins G, NSCLC = non-small cell lung cancer, PD-1 = programmed death receptor 1, PD-L1 = programmed death ligand 1. |\n| --- |\n| Keywords: basal cell carcinoma of the skin, lung squamous cell carcinoma, PD-1 inhibitors, tislelizumab |\n\n1. Introduction  \nBasal cell carcinoma (BCC) is the most common malignant tumor of the skin, with poor growth, less metastasis, and favorable prognosis. Surgical resection is the preferred treatment, with a recurrence rate of 2% to 8% 5 years after the operation. Radiotherapy or systemic treatment can be considered for locally advanced or metastatic BCCs. However, programmed death receptor 1 (PD-1) inhibitors have rarely been used for the treatment of BCC of the skin. In the present case, we found that tislelizumab, a PD-1 inhibitor, was effective in treating both squamous cell carcinoma of the lung and BCC of the skin. In this paper, we report this case and review the literature to provide a reference for the treatment of advanced BCC of the skin.  \n2. Case presentation  \nThe patient was a 74-year-old male. In October 2021, a subcutaneous mass appeared in the left scapular region of his back, which was hard and poorly mobile and gradually increased in size. When the diameter was approximately 3cm, it broke down with pain. The tumor was removed at a local hospital. The pathological diagnosis was (back) BCC. After surgery, the incision did not heal, and the abscess repeatedly broke. There was no significant improvement after reoperation. In December 2021, he developed a cough and coughed a small amount of white, sticky phlegm. Chest computed tomography (CT) showed an irregular mass in the left upper lung, which was considered lung cancer. Bronchoscopy revealed that polypoid neoplasms completely obstructed the left upper lobe bronchus, and lesion invaded the left lower lobe bronchus. The pathological diagnosis was  \nPatient Consent Statement: Informed consent was obtained from the patient and his legal guardian for the purpose of publication.  \nThe authors have no funding and conflicts of interest to disclose.  \nData sharing not applicable to this article as no datasets were generated or analyzed during the current study.  \nEthics statement: We are very grateful to the 940th Hospital of Joint Logistics Support Force of Chinese People Liberation Army for the ethical review and confirmation of this article.  \na Respiratory, The 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, Lanzhou, Gansu Province, China, b Respiratory, The Clinical Medical College of Ningxia Me","cbCailhI2f6ZCscm","https://ap.wps.com/l/cbCailhI2f6ZCscm","pdf",587715,"English","# Abstract\n## Introduction\n## Case presentation\n## Diagnosis\n## Interventions\n## Outcomes\n## Conclusion\n# Keywords\n# 1. Introduction\n# 2. Case presentation","[{\"question\":\"What cancers were diagnosed in this case?\",\"answer\":\"The patient was diagnosed with basal cell carcinoma (BCC) and squamous lung cancer.\"},{\"question\":\"What treatment combination was used?\",\"answer\":\"Docetaxel plus nedaplatin systemic chemotherapy was combined with tislelizumab immunotherapy (PD-1 inhibitor).\"},{\"question\":\"What were the treatment outcomes after tislelizumab?\",\"answer\":\"After two cycles, the lung tumor shrank, the back mass disappeared, and the wound healed, with both cancers significantly reduced in size.\"}]","Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin - A case report | PDF",1790243629]